Hayato Takahashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hayato Takahashi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hiroko Komatsu
Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
1 shared publication - Jun Yamagami
Department of Dermatology, Tokyo Women's Medical University, Tokyo, Japan
1 shared publication - Kaori Yagasaki
Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
1 shared publication - Masayuki Amagai
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
1 shared publication - Takeshi Ouchi
Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-0016, Japan
1 shared publication - Yasuo Hamamoto
Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 2 May 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 27
Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.
- 2 May 2019
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 3 (1) , 27
Open AccessPatient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
With the increased use of targeted therapies in oncology, dermatological adverse events (dAEs) have drawn attention. Because the face is crucial for human identity and social interactions, facial dAEs have significant impact on a patient’s quality of life. This study aimed to explore patients’ experience with regard to the management of targeted oncological therapy-induced facial dAEs. In this qualitative study, 20 patients at a university hospital in Japan with advanced/metastatic cancer and targeted therapy-induced facial dAEs were individually interviewed to collect data. Thematic analysis was used to analyze the data. Patients with cancer and targeted oncological therapy-induced facial dAEs who were referred to the Department of Dermatology had certain expectations from specialist services. Three key themes were identified: professional input and advice, empathetic commitment to individual management, and integrated care across specialties. The referred patients with cancer and facial dAEs needed more in-depth information and advice from dermatological services and were reassured by the empathetic commitment to individual management in integrated care across specialties. These findings suggest that attention to the patient’s perspective with a “sick person first” attitude and a collaborative effort across different specialties is important to minimize the effects of facial dAEs on the quality of life of patients with cancer.